scholarly journals P04.18 Response assessment of bevacizumab for malignant glioma comparison between PET and pathological studies

2017 ◽  
Vol 19 (suppl_3) ◽  
pp. iii44-iii44
Author(s):  
K. Miyake ◽  
D. Ogawa
Keyword(s):  
Malignant Glioma ◽  
Response Assessment

Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. TPS3164-TPS3164
Author(s):  
Martin Kelly Nicholas ◽  
Matthias Holdhoff ◽  
Richard A. Peterson ◽  
Oana Cristina Danciu ◽  
Theodore M. Tarasow ◽  
...  
Keyword(s):  
Phase I ◽  
Malignant Glioma ◽  
Caspase 3 ◽  
Malignant Gliomas ◽  
High Grade Glioma ◽  
Response Assessment ◽  
Cysteine Proteases ◽  
Fixed Dose ◽  
Dose Escalation Study ◽  
Wide Range

TPS3164 Background: The caspase family of cysteine proteases play key roles in the initiation and execution of apoptosis. The activation of procaspase-3 to caspase-3 is critical in both the intrinsic and extrinsic apoptotic cascades. Procaspase-3 levels are elevated in many cancers, including glioblastoma (GBM). As a result, caspase-3 levels are abnormally low in these tumors; thus they avoid apoptosis. PAC-1 is a small molecule that directly activates procaspase-3 and induces apoptosis of cancer cells. PAC-1 has activity against a wide range of cancer cell lines, and in animal models of cancer. PAC-1 crosses the blood brain barrier and has been shown to synergize with TMZ in both canine malignant glioma and meningioma that arise spontaneously. Methods: This Phase I dose escalation study uses a modified- Fibonacci 3+3 design to determine the MTD of PAC-1 when combined with TMZ in patients with recurrent malignant gliomas: anaplastic astrocytoma (AA) and GBM (open to enrollment). Here, we focus on component 2 of the study. Primary objectives: to establish MTD of PAC-1 when combined with a fixed dose of TMZ, tolerability, and toxicity using CTCAE v.4. Secondary and correlative objectives: pharmacokinetics, pharmacodynamics, preliminary anti-tumor activity correlation with procaspase-3 expression in tumor tissue, radiographic response using the Response Assessment in Neuro-Oncology (RANO) criteria, and neurocognitive function using a validated test battery. Inclusion criteria: diagnosis of recurrent high grade glioma (AA or GBM), ECOG PS 0-2, adequate organ function. Exclusion criteria: received prior cytotoxic therapy in the last 3-6 weeks (duration based on prior therapy) or uncontrolled chronic illness. Administration and design, Component 2: PAC-1, orally administered, is dosed at 375-650 mg daily (up to 3 dose levels) on days 1-21 of each 28-day cycle. A fixed dose of TMZ, (150 mg/m2), is administered orally, days 8 -12 of each cycle. The study is currently enrolling patients for Component 2. Clinical trial information: NCT02355535.

Temozolomide plus interferon-β for recurrent malignant glioma patients: Experience of 28 cases.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e13037-e13037
Author(s):  
Zhong-ping Chen ◽  
Qun-ying Yang ◽  
Cheng-cheng Guo
Keyword(s):  
Malignant Glioma ◽  
Objective Response ◽  
Progression Free Survival ◽  
High Grade Glioma ◽  
Response Assessment ◽  
Complete Response ◽  
Recurrent Malignant Glioma ◽  
Interferon Β ◽  
Patients Experience ◽  
Grade Iii

e13037 Background: Previous studies showed that interferon-β may enhance chemosensitivity of temozolomide (TMZ) and nitrosoureas. The present study was to evaluate the efficiency and side effects of TMZ plus INF-β in recurrent malignant glioma patients. Methods: Patients (age≥18 years) with grade III-IV glioma that was progressive or recurrent after prior standard radiotherapy plus TMZ chemotherapy were eligible for the study. Patients were scheduled to receive INF-β 3MU subcutaneous injections on days 1, 3 and 5, while TMZ 200mg/m2orally on days 2 to 6, of a 4-week cycle until tumor progression or unacceptable toxicity. Tumor response was assessed by MRI every 8 weeks. The primary end point was objective response (complete response [CR] plus partial response [PR]) by Response Assessment in Neuro-Oncology Working Group (RANO) criterion. Secondary end points included progression free survival (PFS), overall survival (OS), and toxicity. Results: From July of 2010 to October of 2012, 28 patients were assessed (16 GBM and 12 grade III glioma). There were 22 males and 6 females, and the median age was 44.5 years (ranged from 22 to 73). The median KPS was 80 (70`100). Radiographic responses were noticed in 35.7% (10 of 28) of patients. There was none CR, but 10 PR, 14 stable disease (SD) and 4 progressive disease (PD). The median PFS was 6.0 months (95% CI 3.9-8.0),the median OS was not availability. The most common toxicities include grade±-2 neutropenia(4 cases), thrombocytopenia (3 cases), nausea and vomiting (3 case), fatigue (8 cases) and liver malfunction (3 cases). Grade III or ‡W toxicities were uncommon. Conclusions: Temozolomide plus INF-β has moderate efficacy for recurrent high grade glioma with acceptable toxicity, and thus worth further investigation.

Radiologic response assessment during anti-angiogenic therapy of malignant glioma: a case report

2010 ◽  
Vol 3 (S3) ◽  
pp. 28-29 ◽  
Author(s):  
M. Nowosielski ◽  
M. Hutterer ◽  
D. Putzer ◽  
G. Stockhammer ◽  
W. Recheis ◽  
...  
Keyword(s):  
Case Report ◽  
Malignant Glioma ◽  
Response Assessment ◽  
Angiogenic Therapy

Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI

2012 ◽  
Vol 40 (1) ◽  
pp. 22-33 ◽  
Author(s):  
Norbert Galldiks ◽  
Marion Rapp ◽  
Gabriele Stoffels ◽  
Gereon R. Fink ◽  
Nadim J. Shah ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Response Assessment ◽  
Recurrent Malignant Glioma

scholarly journals Response Assessment of Bevacizumab for Treatment of Malignant Glioma by Neuroimaging

2016 ◽  
Vol 25 (11) ◽  
pp. 912-921 ◽  
Author(s):  
Keisuke Miyake ◽  
Takashi Tamiya
Keyword(s):  
Malignant Glioma ◽  
Response Assessment

scholarly journals Response Assessment in Neuro-Oncology (RANO): more than imaging criteria for malignant glioma

2015 ◽  
Vol 2 (4) ◽  
pp. 205-209 ◽  
Author(s):  
Susan M. Chang ◽  
Patrick Y. Wen ◽  
Michael A. Vogelbaum ◽  
David R. Macdonald ◽  
Martin J. van den Bent
Keyword(s):  
Malignant Glioma ◽  
Clinical Care ◽  
Initial Response ◽  
Response Assessment ◽  
Therapeutic Interventions ◽  
Response To Treatment ◽  
Macdonald Criteria ◽  
Antiangiogenic Therapies ◽  
Tumor Types ◽  
New Criteria

Abstract The introduction of antiangiogenic therapies for the treatment of malignant glioma and the effect of these agents on standard imaging studies were the stimuli for forming a small group of investigators to critically evaluate the limitations of the Macdonald criteria in assessing response to treatment. The initial goal of this group was to highlight the challenges in accurately determining the efficacy of therapeutic interventions for malignant glioma and to develop new criteria that could be implemented in clinical care as well as in the design and conduct of clinical trials. This initial Response Assessment in Neuro-Oncology (RANO) effort started in 2008 and over the last 7 years, it has expanded to include a critical review of response assessment across several tumor types as well as endpoint selection and trial design to improve outcome criteria for neuro-oncological trials. In this paper, we review the overarching principles of the RANO initiative and the efforts to date. We also highlight the diverse and expanding efforts of the multidisciplinary groups of investigators who have volunteered their time as part of this endeavor.

Immunotherapy and Response Assessment in Malignant Glioma

2020 ◽  
Vol 29 (2) ◽  
pp. 95-102
Author(s):  
Stephen J. Bagley ◽  
Arati S. Desai ◽  
MacLean P. Nasrallah ◽  
Donald M. O’Rourke
Keyword(s):  
Malignant Glioma ◽  
Response Assessment

Therapeutic management of malignant glioma in pregnancy: a case report highlighting clinical and radiological features at diagnosis and after intervention

2020 ◽  
Vol 3 (68) ◽  
pp. 147
Author(s):  
Ioniţă Ducu ◽  
Roxana-Elena Bohîlţea ◽  
Dan Teleanu ◽  
Natalia Ţurcan ◽  
Monica Mihaela Cîrstoiu
Keyword(s):  
Case Report ◽  
Malignant Glioma ◽  
Therapeutic Management ◽  
Radiological Features ◽  
In Pregnancy
Sign in / Sign up

Export Citation Format

Share Document